Healing enhancement with administration of local trafermin( bFGF) in patients at high risk of MRONJ presenting with delayed socket healing and bone exposure after tooth extraction, a single arm pilot study

开始日期2026-08-17

申办/合作机构-

JPRN-jRCT2051230028

/ Not yet recruiting临床3期

Regenerative Therapy for Soft Tissue Defects of the External Auditory Meatus with NPC-18

开始日期2023-05-01

申办/合作机构-

JPRN-jRCTs031220681

/ Recruiting临床2期

Evaluation of therapeutic effect of intracordal bFGF administration on vocal fold paralysis

开始日期2023-03-03

申办/合作机构-

100 项与曲弗明相关的临床结果

登录后查看更多信息

100 项与曲弗明相关的转化医学

登录后查看更多信息

100 项与曲弗明相关的专利（医药）

登录后查看更多信息

项与曲弗明相关的文献（医药）

2026-10-01·International Wound Journal

Early Outpatient bFGF ‐Based Wound Care for Foot Lesions in Haemodialysis Patients: A Real‐World Stepwise Limb‐Salvage Strategy From Japan

Article

作者: Tamaki, Motoyuki ; Tamaki, Masaharu ; Akita, Sadanori ; Tamaki, Masanori ; Hayashi, Hiroyuki

ABSTRACT:

Haemodialysis patients face a markedly elevated risk of foot lesions because of coexisting diabetes mellitus (DM), peripheral arterial disease (PAD) and uremia‐related impairment of wound healing. Structured outpatient strategies and the optimal place of basic fibroblast growth factor (bFGF) within a stepwise algorithm remain poorly defined. To report complete healing and its durability in haemodialysis patients treated with bFGF for foot lesions, and to propose a stepwise limb‐salvage algorithm with prespecified escalation criteria in which bFGF precedes dehydrated human amnion/chorion membrane (dHACM) or surgery. Retrospective observational case series of 20 haemodialysis patients receiving bFGF (trafermin; Fiblast Spray) for foot lesions across three outpatient wound‐care programmes. Wound status was documented by area, depth, tissue exposure and WIfI classification; perfusion was assessed in every patient by toe‐brachial and ankle‐brachial indices, duplex ultrasonography and angiography, independently of any pre‐existing recorded diagnosis. Complete healing was defined a priori as 100% re‐epithelialization confirmed on two consecutive visits at least 2 weeks apart. Tier entry criteria and escalation triggers were prespecified, using a wound‐area reduction below 50% at 4 weeks as the principal threshold. The broader haemodialysis population ( n = 212) served as contextual comparator. Mean age was 75.0 ± 7.3 years (range, 59–92); there were six men and 14 women. DM was present in 15 patients (75.0%) and registry‐recorded PAD in 8 (40.0%), against 56.6% and 17.9% in the broader population; objective testing identified hemodynamically significant PAD in 12 patients (60.0%), all of whom were revascularized. Mean baseline wound area was 5.5 ± 3.4 cm (2), and WIfI stages 1–4 comprised 5, 8, 6 and 1 patients. Twelve patients (60.0%) were managed with bFGF alone, five (25.0%) required dHACM and three (15.0%) required surgery. Complete healing was achieved in 18 of 20 patients (90.0%) at a mean of 8.9 ± 4.4 weeks, with no amputation of any level. Over a median follow‐up of 13.0 months (range, 6–28), recurrence at the same site occurred in two patients (10.0%); amputation‐free survival at 12 months was 100% and overall survival 95%. The bFGF‐treated cohort carried a disproportionate burden of DM and PAD, supporting targeted early biologic intervention in this highest‐risk subgroup. Within a stepwise algorithm combining objective perfusion assessment with prespecified escalation criteria, 90% of wounds healed completely without amputation, providing a practical limb‐salvage framework for this vulnerable population.

2026-10-01·INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED

Collagen sponge combined with recombinant human basic fibroblast growth factor for refractory venous leg ulcers: A prospective controlled study evaluating healing, skin graft avoidance, and costs

Article

作者: Zhu, Yixin ; Cheng, Juntao ; Wei, Zhiyi ; Kang, Rudian ; Lai, Qinghua ; Yang, Shaodong

BACKGROUND:

Refractory venous leg ulcers (VLUs) represent a significant clinical challenge, often requiring surgical intervention with skin grafting. This study evaluated whether a collagen sponge combined with recombinant human basic fibroblast growth factor (rh-bFGF) could accelerate healing, reduce the need for skin grafting, lower costs, and improve scar quality compared with standard alginate dressings.

METHODS:

This prospective controlled study enrolled 120 patients with CEAP C6 VLUs refractory to standard compression therapy. Patients were allocated to treatment with either a collagen sponge saturated with rh-bFGF (n = 60) or standard alginate dressing (n = 60), both under compression therapy. The primary endpoint was complete wound healing at 4 weeks. Secondary endpoints included time-to-healing (analyzed by Kaplan-Meier with log-rank test), need for skin grafting, total hospitalization costs, and scar quality assessed by the Vancouver Scar Scale (VSS) at 3 months. Multivariable Cox regression was used to adjust for potential confounders.

RESULTS:

The CS + rh-bFGF group achieved a significantly higher 4-week healing rate (85.0% vs. 55.0%; risk difference: 30.0%, 95% CI: 15.2-44.8; p < 0.001). Median healing time was shorter in the treatment group (26 days vs. 44 days; log-rank p < 0.001), with an adjusted hazard ratio of 2.54 (95% CI: 1.71-3.78). No patient in the treatment group required skin grafting compared with 13 patients (21.7%) in the control group (p < 0.001). Total hospitalization costs were lower in the treatment group (¥14,850 ± 2420 vs. ¥22,160 ± 4150; mean difference: ¥7310, 95% CI: ¥5890-¥8730; p < 0.001). Scar quality was superior in the treatment group (VSS: 3.6 ± 1.1 vs. 5.8 ± 1.5; mean difference: 2.2, 95% CI: 1.7-2.7; p < 0.001). Adverse event rates were comparable between groups (6.7% vs. 10.0%, p = 0.512).

CONCLUSIONS:

In this prospective controlled study of 120 patients with refractory VLUs, the combination of a collagen sponge and rh-bFGF was associated with faster healing, elimination of skin grafting, reduced hospitalization costs, and superior scar quality compared with standard alginate dressings. These findings suggest that this approach warrants evaluation in randomized controlled trials to establish its role in clinical practice.

2026-10-01·International Journal of Surgery Case Reports

Strategic wound and nutritional management for short bowel syndrome and wound dehiscence following non-occlusive mesenteric ischemia: a case report.

Article

作者: Miura, Tomoya ; Yambe, Kenichiro ; Kitamura, Yoh ; Nakagawa, Kei ; Nakano, Toru ; Tsujinaka, Shingo

Introduction and importance:

Non-occlusive mesenteric ischemia (NOMI) is life-threatening and may require extensive bowel resection, resulting in short bowel syndrome (SBS), nutritional deficiencies, and impaired wound healing. Severe wound dehiscence further complicates postoperative management, and reports describing this sequence are limited. This report highlights coordinated, phase-oriented management in an immunocompromised patient.

Presentation of case:

An 81-year-old female receiving immunosuppressive therapy underwent emergency Hartmann's procedure for perforated sigmoid diverticulitis. Postoperative septic shock required vasopressor support. On postoperative day (POD) 9, NOMI was diagnosed, necessitating subtotal small bowel resection and total colectomy, leaving approximately 70 cm of jejunum with an end jejunostomy. Extensive wound dehiscence developed by POD 21. Management included debridement, povidone-iodine sugar paste, 4 weeks of negative-pressure wound therapy with instillation, and trafermin. Complete secondary-intention closure without skin grafting was achieved by POD 90. Enteral and oral nutrition were gradually introduced while parenteral support was continued, and the high-output stoma was controlled with antidiarrheal agents and proton-pump inhibitors. The patient was transferred for rehabilitation on POD 120. At 15 months, she remained well, tolerated a regular diet, and required parenteral nutrition only on weekends.

Clinical discussion:

Delayed NOMI should be considered after septic shock despite transient hemodynamic stabilization. Phase-oriented wound care, staged nutritional escalation, and stoma output control supported secondary-intention healing without reconstructive surgery in a patient with SBS-related malnutrition.

Conclusion:

Coordinated wound and nutritional management may enable sustained recovery after NOMI complicated by SBS, high-output stoma, and extensive wound dehiscence.

项与曲弗明相关的新闻（医药）

2026-01-13

·津津药道

强生、Numab、科研制药之间的“三角恋”

2024年5月，强生以12.5亿美元的现金价格从瑞士Numab获得NM26（IL-4Rα/IL-31双抗）用于治疗特应性皮炎（AD）。然而仅18个月后的2025年12月，强生宣布因2b期临床中期分析结果未达预期，终止NM26（JNJ-5939）的继续开发。值得注意的是，NM26在日本、中国、韩国和其它亚洲地区的商业权利早在2021年就被日本科研制药（Kaken Pharmaceutical）购得。更有趣的是，在2024年12月，强生以首付3000万美元、超12亿美元里程碑的价格与科研制药合作开发口服STAT6（信号转导及转录激活因子6）抑制剂KP-723。强生获得KP-723在全球（除日本外）的开发、制造及商业化独家权利。科研制药保留在日本的商业化权利，且强生拥有在日本进行共同推广的优先选择权。根据协议，科研制药负责推进KP-723的1期临床试验。而该试验已于2025年启动，旨在评估其在AD患者中的安全性及药代动力学。在1期临床试验完成后，强生将全面接手该药物的全球临床开发和商业化工作。强生、Numab、科研制药之间在AD领域呈现出既合作又竞争的复杂关系（图1）。图1. 强生、Numab、科研制药关系图强生拥有全球顶级的临床、注册、商业化能力，同时在AD领域做了广泛的布局，吸引了包括Numab及科研制药在内的中小药企与其合作。而Numab及科研制药这样的中小药企之间的合作、取长补短也是推动创新药研发的重要方式。 2025年12月，美国麻省的Kymera Therapeutics宣布，其first-in-class STAT6 PROTAC药物KT-621在中重度AD患者中开展的BroADen 1b期临床试验取得积极结果。 KT-621在100mg和200mg剂量组均实现显著的STAT6降解，皮肤和血液中STAT6水平中位数分别降低94%和98%，展现出从健康志愿者到AD患者的良好转化效果。同时，KT-621可显著降低血液中多种2型疾病相关生物标志物水平，减少皮损部位核心2型炎症及AD相关基因集表达。 STAT6是IL-4和IL-13细胞因子信号传导的关键节点，这些细胞因子是AD和哮喘等2型炎症疾病的核心驱动因素。口服型STAT6抑制剂被视为挑战杜普利尤单抗等注射用生物制剂的“下一代”疗法。与PROTAC降解剂KT-621结构不同，KP-723通过直接结合STAT6蛋白（可能是其SH2结构域），抑制其磷酸化、二聚化或与受体的结合，从而阻断信号传导（图2）。因此KP-723分子量相对较小，不含庞大的E3连接酶配体，在口服生物利用度和细胞渗透性方面具有天然优势。图2. STAT6信号通路日本百年药企科研制药并不为大多数中国制药人熟知，其历史最早可以追溯到1917年成立的理化学研究所（RIKEN），它是日本极具科研背景的特色药企。其发展历程可分为以下四个主要阶段： 1. 理研背景与诞生（1917年-1948年）理研起源：1917年，作为日本唯一的自然科学综合研究所——理化学研究所（RIKEN）成立。科研化学成立：1948年3月，为了将理化学研究所的研究成果实现商业化，科研化学株式会社正式成立。当时的主要任务是利用研究所的尖端技术生产稀缺药品（如青霉素）。 2. 核心产品的突破（1948年-1980年代）抗真菌药奠基：20世纪50年代起，公司深耕真菌感染领域。1959年，公司推出了具有里程碑意义的抗真菌抗生素钝曲霉素（Variotin）。正式更名：1982年，科研化学株式会社与化研化学株式会社合并，正式更名为现名：科研制药株式会社。整形外科突围：1987年，公司推出了用于治疗骨关节炎的透明质酸钠注射液ARTZ。该产品后来成为日本乃至全球整形外科领域的重磅产品，奠定了公司在该领域的领导地位。 3. 专业化与全球化（1990年代-2010年代）皮肤科巨头地位确立：2014年，公司推出了日本首个用于治疗甲真菌病的外用抗真菌药Clenafin（艾氟康唑）。这款产品不仅在日本取得巨大成功，还通过授权在全球多个国家（包括美国和中国）销售，成为公司的“现金奶牛”。创新手术产品：2001年推出了用于促进伤口愈合的喷雾剂Fiblast（重组人碱性成纤维细胞生长因子），进一步强化了其在外科和皮肤科的竞争力。 4. 2020年代及未来：向“科研驱动型全球专科药企”转型结构性改革（2020年至今）：面对日本国内药品降价压力，公司制定了《2031年长期经营计划》，重点从“销售驱动”转向“研发驱动”。 BD交易爆发期：自2023年以来，公司通过频繁的国际合作（如与Alumis合作TYK2抑制剂、与Numab合作多抗[NM81]）加速进入免疫学和罕见病领域。 2025年最新动向：公司正积极剥离低效率的非核心业务，并在2025年重点推进数字化转型（SaMD）和AI辅助药物开发，以期在2030年后实现全球化扩张。科研制药的历史体现了从“学术研究转化机构”到“皮肤/骨科专科药企”，再到如今“全球免疫学挑战者”的演变。尽管规模属于中型，但其凭借在特定治疗领域（如甲真菌病、关节炎）的深厚技术积淀，在日本制药界占有不可替代的地位。科研制药作为日本皮肤科市场的“守门人”，其2025年引进的TYK2抑制剂（ESK-001）与强生的资产在AD领域虽有竞争，但在联合用药研究上存在合作想象空间。

临床1期蛋白降解靶向嵌合体临床2期引进/卖出临床结果

2025-12-25

·科途医学K2Oncology

文献解读丨【Cell Research重磅研究】突破PDO瓶颈：结肠癌类器官模型揭示FGF2-AP-1信号轴的关键作用

DOI：10.1038/s41422-025-01139-y 2025年7月4日，由北京大学的熊亮、徐颖和高昭娅作为共同第一作者主导完成，通讯作者为北京大学医学部的古槿、邓宏魁和曲茂龙研究员的一项研究《A patient-derived organoid model captures fetal-like plasticity in colorectal cancer》发表在Cell Research，本研究团队汇聚了基础医学、胃肠外科、肿瘤学、生物信息学等多个领域的专家，体现了深厚的多学科交叉研究背景。本研究的核心思想正是通过化学小分子替代不稳定的蛋白因子，构建一个全新的、化学限定的结直肠癌系统，以稳定地捕捉和研究结直肠癌中最具侵袭性的胎儿样可塑性状态。为此，纪念斯隆-凯特琳癌症中心结直肠外科的Chao Wu、Min Jung Kim及MD安德森癌症中心的J. Joshua Smith(通讯作者)为本研究成果撰写述评，发表于2025年8月29日的Cell Research，他们从临床实践与转化研究的双重角度，对熊亮等人开发的类器官新技术平台及其在结直肠癌胎儿样可塑性研究中的价值进行了专业解读与展望。下面，我们就为读者解读这篇论文的重点内容：背景简介：肿瘤可塑性与现有模型的局限表型可塑性是驱动癌症进展、转移和治疗耐药的关键特征。在结直肠癌中，这种可塑性与胎儿样转录程序（Fetal-like Transcriptional Programs）的重新激活密切相关。这些在胚胎发育过程中活跃的基因表达模式，在肿瘤受到炎症、损伤或化疗等环境应激时重新出现，驱使癌细胞进入高度可塑的状态，获得再生和适应环境压力的能力。然而，对这些胎儿样状态在结直肠癌中作用机制的研究长期受制于体外模型的不足。传统的患者来源类器官培养体系最初旨在维持成人肠道上皮细胞，它们面临两大挑战： 1.因子不稳定：培养基中的关键蛋白因子不稳定且来自异源，难以在长期培养中维持精确的信号通路，导致胎儿样或耐药亚群逐渐丢失。 2.选择压力：传统条件倾向于优势克隆的扩增，引入了选择压力，限制了可塑性细胞状态的保持。 1 本研究的主要发现与结论：开发了革命性的类器官培养系统（CiPDOs）：针对传统患者来源类器官无法长期维持肿瘤细胞“胎儿样可塑性”这一关键局限，研究团队成功构建了一种化学成分明确的培养系统（4C系统，含EGF, CHIR99021, LDN-214117和FGF2）。该系统能够实现结肠癌细胞的长期扩增，并稳定保留其在高级别肿瘤中特有的胎儿样转录特征。定义并验证了关键的“癌胎状态（OnFS）”：通过整合泛癌种单细胞图谱与胎儿肠道基因特征，本研究鉴定出一个由28个基因构成的OnFS特征。该状态在晚期（III/IV期）、发生淋巴结转移及治疗耐受的结直肠癌患者中显著富集，并与患者的不良预后密切相关。OnFS细胞表现出上皮-间质可塑性增强、侵袭和转移能力提升以及对标准化疗放疗的抵抗性。揭示了核心的调控信号轴（FGF2-AP-1）：机制研究表明，OnFS的维持依赖于一条此前未被充分认识的FGF2-AP-1信号轴。其中，转录因子AP-1（特别是JUND和FOS）是维持OnFS及相关恶性表型所必需的。抑制该轴可有效削弱OnFS特征，并降低癌细胞的侵袭性和耐药性。功能表型重现：模型稳定地重现了结直肠癌细胞的上皮-间充质可塑性增强、侵袭性增强和对一线放化疗的持续耐药等恶性特征。 2 文章重点：致癌-胎儿状态（OnFS）的临床意义与机制驱动图1：化学限定培养系统在患者来源结直肠癌类器官模型中实现胎儿样可塑性的长期维持 OnFS的鉴定与预后价值由于已发表的胎儿基因签名在CRC中应用有限，本研究通过整合泛癌数据和胎儿肠道基因集，鉴定出一个新的、更具临床相关性的28基因OnFS签名。富集标记物：OnFS细胞富集表达MSLN、TROP2和ANXA1等胎儿相关基因。临床关联：OnFS评分的升高，与CRC的晚期临床分期III+IV、高组织学分级、以及对新辅助放化疗的无病理完全缓解反应显著相关。这有力地将OnFS状态确定为CRC不良预后和治疗抵抗的可靠生物标志物。本研究成功开发了一种创新的化学限定患者来源结直肠癌类器官平台，解决了传统体系难以长期维持胎儿样可塑性状态的瓶颈。通过这一平台，研究人员不仅鉴定出一种具有高度临床相关性的致癌-胎儿状态，更重要的是，明确了其背后的信号轴调控机制。值得注意的是，CiPDOs可以在不同基因型（如KRAS、TP53、BRAF突变）的患者样本中维持高度一致的OnFS相关表型，支持了肿瘤转移和耐药性主要源于非遗传性表型重编程的观点。本研究突破性进展与意义：技术突破：CiPDOs模型成功解决了癌症研究领域的一个长期挑战——如何在体外培养中真实地模拟并维持肿瘤细胞的动态可塑性状态。这为研究癌症进展、转移和耐药中最恶性的细胞亚群提供了强大的实验平台。理论创新：本研究不仅发现了一个具有明确临床预后价值的OnFS，还将其与经典的干细胞程序区分开来，深化了学界对肿瘤细胞身份“可塑性”的理解，而非简单的“干细胞性”。临床与转化价值：该研究揭示了FGF2-AP-1信号轴作为潜在的治疗靶点，为针对具有高度可塑性和耐药性的癌细胞亚群提供了新的干预思路。同时，OnFS特征本身有望发展成为预测结肠癌患者预后和治疗反应的生物标志物。总之，这项工作通过一项创新的技术模型，揭示了驱动结肠癌恶性进展的核心细胞状态及其调控机制，为理解并最终攻克肿瘤的可塑性和治疗抵抗开辟了新的道路。欢迎各位咨询——科途官方客服：关于科途医学科途医学是一家专注于类器官培养全流程产品、类器官建模服务、类器官疾病模型库建设、临床前药物发现、转化医学CRO服务的高科技公司，可提供类器官一站式解决方案。基于分泌蛋白质组学筛选技术，公司已经建立了40多种组织的类器官培养方法。产品包括EHSgel 基质胶、多种类器官培养基、类器官相关细胞因子、组织消化酶解液、类器官分离回收液、类器官冻存液等。我们致力于提供高质量、更可靠的类器官产品，助力客户科学研究的进展，欢迎您来电咨询。使用科途医学类器官产品或模型发表的科研文献列表(部分) 订购及业务咨询：info@K2Oncology.com 技术服务咨询：TechSupport@k2oncology.com 联系电话：010-67889128，13371633638（微信同步），17778038351 网址：www.K2Oncology.com 地址： ●北京市北京经济技术开发区经海六路5号院东尚·E园10号楼1层109 ●浙江省湖州市红丰路1366号6幢10楼1001室 ●河北省廊坊市固安县新兴园肽谷生物医药加速器产业园1号楼A1-1-4室

2025-08-06

·FierceBiotech

Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria’s navenibart in Japan

Today’s deal is a good fit for Tokyo-based Kaken, which scooped up the Japan rights to another late-stage HAE asset in April.\n Kaken Pharmaceutical is paying $16 million upfront for the Japanese rights to Astria Therapeutics’ phase 3-stage hereditary angioedema (HAE) drug.Astria took the candidate, a monoclonal antibody inhibitor of plasma kallikrein called navenibart, into a late-stage study off the back of a phase 1b/2 trial last year that tied the drug to up to a 92% reduction in HAE attacks at six months.In return for the rights to develop and commercialize navenibart in its home territory of Japan, Kaken is handing over $16 million upfront, with potentially another $16 million to follow in commercialization and sales milestones. Astria could also be in line for tiered royalties on net sales and partial reimbursement for its phase 3 costs.“We are thrilled to partner with Kaken for the development and commercialization of navenibart in Japan, which advances our strategy to enable broad access to navenibart globally,” Astria CEO Jill Milne, Ph.D., said in an August 6 release.“In addition to our shared values that put patients first, Kaken brings strong relationships with the Japanese medical community that we believe will support both our phase 3 Alpha-Orbit trial as well as the potential commercialization of navenibart in the future,” Milne added.HAE is a genetic disease marked by low levels or dysfunction of the C1 inhibitor. Patients can be struck with bouts of severe swelling across the body, and attacks can be fatal if they impact the lungs.CSL’s HAE preventative treatment Andembry was approved in Japan earlier this year, before gaining the go-ahead from the FDA in June. It set up CSL to take on Takeda’s blockbuster Takhzyro and BioCryst Pharmaceuticals’ fast-rising Orladeyo in a competitive market to treat patients with the rare genetic condition.Today’s deal is a good fit for Tokyo-based Kaken, which scooped up the Japan rights to another late-stage HAE asset in April in the form of KalVista Pharmaceuticals’ sebetralstat. The drug was approved by the FDA last month under the brand name Ekterly. Earlier in the year, Kaken also acquired the Japanese rights to develop Alumis’ late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan.Kaken already markets a variety of products in Japan, including hyaluronate sodium for osteoarthritis and Fiblast for skin ulcers. The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics and tildacerfont from Spruce Biosciences for congenital adrenal hyperplasia.“Our partnership with Astria for the development and commercialization of navenibart supports our strategy of providing therapies that address unmet medical needs in the Japanese community,” Kaken’s president, Hiroyuki Horiuchi, said in today’s release.“We believe that navenibart is a complementary fit with our HAE portfolio, providing patients in Japan with the potential for low-burden treatments to better manage their disease,” Horiuchi added.

临床3期上市批准引进/卖出

100 项与曲弗明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03362	曲弗明	D03AX15 D03	DB06244

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
鼓膜穿孔	日本	Nobelpharma Co., Ltd.	2019-09-20
牙周炎	日本	Kaken Pharmaceutical Co., Ltd.	2016-09-28
褥疮	日本	Kaken Pharmaceutical Co., Ltd.	2001-04-04
皮肤溃疡	日本	Kaken Pharmaceutical Co., Ltd.	2001-04-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病足溃疡	临床3期	捷克	Olympus Biotech Corp.	2010-11-01
糖尿病足溃疡	临床3期	法国	Olympus Biotech Corp.	2010-11-01
糖尿病足溃疡	临床3期	匈牙利	Olympus Biotech Corp.	2010-11-01
糖尿病足溃疡	临床3期	意大利	Olympus Biotech Corp.	2010-11-01
牙槽骨质丢失	临床3期	日本	Kaken Pharmaceutical Co., Ltd.	2008-08-01
牙周附着丢失	临床3期	日本	Kaken Pharmaceutical Co., Ltd.	2008-08-01
胫骨骨折	临床2期	日本	Kaken Pharmaceutical Co., Ltd.	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01217463 (TRANS-South, CTgov)	临床3期	糖尿病足溃疡	201	Trafermin 0.01% spray (Trafermin 0.01% Spray)	顧憲築築遞餘廠齋鏇積 = 鹽淵獵鹹醖窪艱構簾夢糧鬱醖齋齋選選觸鑰憲 (獵遞醖膚選築鹽蓋繭製, 憲簾艱範製膚繭鑰醖選 ~ 鑰範衊淵夢積簾簾構觸)	-	2014-08-05
				Trafermin 0.01% spray (Matching Placebo Spray)	顧憲築築遞餘廠齋鏇積 = 網衊鹽鹹齋襯夢窪選糧糧鬱醖齋齋選選觸鑰憲 (獵遞醖膚選築鹽蓋繭製, 鹹網鹽憲膚觸鏇餘選糧 ~ 範襯鑰簾鑰鹽鬱構獵簾)
NCT01217476 (TRANS-North, CTgov)	临床3期	糖尿病足溃疡	207	Trafermin (Trafermin)	鹹衊鑰醖構襯廠顧簾範 = 窪繭積獵鬱齋築網廠鹹壓鹽築製夢壓積淵糧壓 (膚遞鑰網網願積衊鹽獵, 願選簾築襯窪簾範遞鹽 ~ 膚醖餘願壓遞窪窪膚齋) 更多	-	2014-08-05
				placebo (Placebo)	鹹衊鑰醖構襯廠顧簾範 = 遞餘膚膚夢齋獵願憲鬱壓鹽築製夢壓積淵糧壓 (膚遞鑰網網願積衊鹽獵, 網選鏇蓋顧衊醖鬱膚網 ~ 築窪廠齋鹹鏇範憲構淵) 更多